Apricus Biosciences is a biopharmaceutical company which focuses on the development and commercialization of product candidates in the areas of urology and rheumatology. Its lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. The Company also engages in developing other medicines to treat rheumatoid and urological disease.

Type
Public
HQ
San Diego, US
Founded
1987
Size (employees)
15 (est)
Apricus Biosciences was founded in 1987 and is headquartered in San Diego, US
Report incorrect company information

Apricus Biosciences Office Locations

Apricus Biosciences has an office in San Diego
San Diego, US (HQ)
11975 El Camino Real, Ste 300
Show all (1)
Report incorrect company information

Apricus Biosciences Financials and Metrics

Apricus Biosciences Financials

Apricus Biosciences's revenue was reported to be $5.76 m in FY, 2016 which is a 19.1% increase from the previous period.
USD

Net income (Q1, 2018)

(2.3 m)

Market capitalization (23-May-2018)

6.8 m

Closing share price (23-May-2018)

0.3

Cash (31-Mar-2018)

5.7 m
Apricus Biosciences's current market capitalization is $6.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

2.5 m9.3 m4.8 m5.8 m

Revenue growth, %

269%(48%)19%

Cost of goods sold

23 k918 k922 k511 k

Gross profit

2.5 m8.3 m3.9 m5.3 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

28 k5.5 m1.9 m475 k462 k1.3 m626 k464 k4.3 m

Cost of goods sold

75 k485 k233 k509 k142 k233 k93 k111 k

Gross profit

5.4 m1.4 m242 k(47 k)1.1 m393 k371 k4.2 m

Gross profit Margin, %

99%74%51%(10%)89%63%80%97%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

21.4 m11.4 m3.9 m2.1 m6.3 m

Accounts Receivable

59 k678 k519 k530 k

Inventories

336 k275 k469 k764 k

Current Assets

22.3 m13.3 m6.3 m3.6 m6.6 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

20.6 m22.5 m17.4 m16.2 m7.4 m5.8 m6.9 m2.7 m5.6 m3.8 m7.8 m8.5 m5.7 m

Accounts Receivable

35 k69 k49 k513 k664 k575 k688 k687 k398 k

Inventories

338 k364 k377 k217 k411 k142 k405 k778 k800 k

Current Assets

21.7 m23.5 m18.8 m18 m9.8 m8.2 m9.1 m4.9 m7.2 m5.1 m8.6 m8.7 m5.9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(16.9 m)(21.8 m)(19 m)(7.4 m)321 k

Depreciation and Amortization

77 k170 k300 k289 k117 k

Inventories

(341 k)61 k(194 k)(295 k)

Accounts Payable

(920 k)(66 k)609 k(509 k)(705 k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(15.6 m)(3.3 m)(1.4 m)(4.5 m)(6.4 m)(5 m)(2.5 m)(3.3 m)(7.1 m)8.1 m(2.3 m)

Depreciation and Amortization

57 k20 k40 k102 k13 k

Inventories

(338 k)(28 k)(41 k)15 k217 k411 k142 k405 k778 k800 k

Accounts Payable

(1.5 m)67 k202 k295 k880 k446 k417 k1.1 m1.6 m1.4 m485 k286 k
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information